Progression-free survival
Progression-free survival (PFS) is the time from the start of treatment until disease progresses or the patient dies of any cause, whichever comes first.
Progression-free survival (PFS) is the time from the start of treatment until disease progresses or the patient dies of any cause, whichever comes first. It differs from overall survival (OS) in counting progression as an event, which makes it reachable far sooner and with fewer patients — the reason it has become a common primary endpoint in oncology trials and a frequent basis for regulatory approval, particularly where long post-progression survival would make an OS trial impractically large or slow. It is assessed by standardized radiologic criteria, most often RECIST, and is reported alongside objective response rate and duration of response.
Its weaknesses are consequences of how it is measured. Progression is detected only when a scan is performed, so PFS is interval-censored and its apparent value depends on the imaging schedule; unequal or unblinded assessment between arms biases the result, which is why blinded independent central review is used to check investigator assessment. Patients who stop treatment for toxicity and are no longer scanned may be censored informatively, in a manner correlated with the outcome being measured. And because death from any cause counts as an event, PFS counts mortality as an event, though it is generally unaffected by therapies given after progression.
The deeper question is what it stands for. PFS is valuable as a direct measure of disease control and of the interval before a patient's cancer worsens, but its correlation with overall survival is inconsistent across tumor types and drug classes, and a statistically significant PFS gain of a few weeks may not correspond to any survival or symptom benefit. This gap is sharpest with checkpoint inhibitor regimens, where delayed separation of curves and pseudo-progression complicate the endpoint further. PFS remains useful for comparing treatment sequencing strategies and identifying prognostic factors, and in lung cancer, renal cell carcinoma, multiple myeloma and other solid tumors it is routinely reported — but as a surrogate for survival it requires validation within each specific setting rather than assumption.
Where the papers sit
12 papers from the last 6 months study progression-free survival directly · updated from PubMed 8 Nov 2026
Study type 4 clinical trials · 6 observational · 2 human data
Themes 3 themes
-
Advanced Cancer Combination Therapies
Advanced cancers are increasingly treated with combinations pairing targeted agents, chemotherapy, radiotherapy, or hormonal therapy with immune or DNA-repair strategies. In renal cell carcinoma, lenvatinib-based approaches are compared with cabozantinib and checkpoint inhibition, while toripalimab regimens extend combination therapy into other carcinomas. Prostate cancer work combines PARP and androgen-signaling inhibition with ADT, and mismatch-repair–deficient digestive cancers highlight immune-related toxicity. The recurring question is whether deeper disease control justifies added adverse events, with no universal regimen established.
5 papers · 41.7%
-
Multiple Myeloma Treatment Sequencing
Frontline daratumumab-based quadruplets are improving disease control over VRd in transplant-eligible multiple myeloma. Later lines increasingly use CAR T-cell therapies and bispecific antibodies, with treatment order becoming a major determinant of long-term survival in relapsed disease. The evidence centers on progression, death, hazard ratios, and follow-up rather than a single preferred sequence. Optimal placement of cellular and bispecific therapies remains open.
2 papers · 16.7%
-
Others — Cancer Outcomes Across Tumors
Treatment outcomes range from intensive transplantation for primary CNS lymphoma to radiotherapy for extremity sarcoma and cachexia management in NSCLC. Other work develops PFS nomograms for systemic anaplastic large cell lymphoma or evaluates circulating tumour DNA in nonmetastatic head and neck cancer. The shared focus is prognostication, treatment benefit, and toxicity across malignancies, not one biological mechanism. No common therapeutic direction emerges.
5 papers · 41.7%
Papers
The 12 papers from the last 6 months that study progression-free survival directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Advanced Cancer Combination Therapies (5)
- Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet (London, England) · 12 Aug 2026 PMID 42586114
- Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
- Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498484
- Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498483
- PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. The New England journal of medicine · 1 Jun 2026 PMID 42223064
Multiple Myeloma Treatment Sequencing (2)
- Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
- Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia · 24 Jun 2026 PMID 42342528
Others — Cancer Outcomes Across Tumors (5)
- Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD). JMIR research protocols · 5 Nov 2026 PMID 42987275
- An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study. Hematology (Amsterdam, Netherlands) · 12 Aug 2026 PMID 42584691
- Radiotherapy for Soft-tissue Sarcoma of the Extremities: A 10-Year Analysis of Treatment Outcomes and Toxicity at a Large Sarcoma Centre. Anticancer research · 29 Jul 2026 PMID 42527052
- High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. Lancet (London, England) · 22 Jul 2026 PMID 42486133
- A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA). Journal of cachexia, sarcopenia and muscle · 7 Jul 2026 PMID 42411631
By study type
Clinical trials (4)
- Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet (London, England) · 12 Aug 2026 PMID 42586114
- Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498484
- High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. Lancet (London, England) · 22 Jul 2026 PMID 42486133
- PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. The New England journal of medicine · 1 Jun 2026 PMID 42223064
Observational studies and case reports (6)
- Evaluation of the Clinical Utility of Circulating Tumor DNA in the Management of Patients With Nonmetastatic Head and Neck Cancer: Protocol for a Prospective Bicentric Study (CIRVAD). JMIR research protocols · 5 Nov 2026 PMID 42987275
- An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study. Hematology (Amsterdam, Netherlands) · 12 Aug 2026 PMID 42584691
- Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors. Anticancer research · 29 Jul 2026 PMID 42527074
- Radiotherapy for Soft-tissue Sarcoma of the Extremities: A 10-Year Analysis of Treatment Outcomes and Toxicity at a Large Sarcoma Centre. Anticancer research · 29 Jul 2026 PMID 42527052
- Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future oncology (London, England) · 14 Jul 2026 PMID 42444515
- A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA). Journal of cachexia, sarcopenia and muscle · 7 Jul 2026 PMID 42411631
Human data, design not indexed (2)
- Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy. Journal for immunotherapy of cancer · 24 Jul 2026 PMID 42498483
- Impact of Treatment Sequencing With CAR T-cell Therapies and Bispecific Antibodies on Long-term Survival in 4L+ RRMM in the United States: A Simulation Model. Clinical lymphoma, myeloma & leukemia · 24 Jun 2026 PMID 42342528
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-08-03. Last written: 2026-08-26 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.